Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.

Doria C, Leali PT, Solla F, Maestretti G, Balsano M, Scarpa RM.

Clin Cases Miner Bone Metab. 2016 Sep-Dec;13(3):195-199. doi: 10.11138/ccmbm/2016.13.3.195. Epub 2017 Feb 10.

2.

Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.

Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V, Cassibba S, Cesareo R, Chiodini I, Francucci CM, Gianotti L, Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A, Vignali E, Rochira V, Zini M.

J Endocrinol Invest. 2016 Jul;39(7):807-34. doi: 10.1007/s40618-016-0434-8. Epub 2016 Mar 11.

3.

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group..

Lancet Oncol. 2016 Feb;17(2):243-56. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21. Review. Erratum in: Lancet Oncol. 2016 Feb;17(2):e46.

4.

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.

Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, Scrase CD, Robertson A, Cafferty F, Welland A, Carpenter R, Honeyfield L, Abel RL, Stone M, Parmar MK, Abel PD.

Eur Urol. 2016 Jun;69(6):1016-25. doi: 10.1016/j.eururo.2015.11.030. Epub 2015 Dec 17.

5.

Male Osteoporosis in the Elderly.

D'Amelio P, Isaia GC.

Int J Endocrinol. 2015;2015:907689. doi: 10.1155/2015/907689. Epub 2015 Sep 20. Review.

6.

Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.

Bienz M, Saad F.

Bonekey Rep. 2015 Jun 24;4:716. doi: 10.1038/bonekey.2015.85. eCollection 2015. Review.

7.

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North S, Rendon R, So A, Usmani N, Vigneault E, Fleshner NE.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.

8.
9.

Medication-induced osteoporosis: screening and treatment strategies.

Panday K, Gona A, Humphrey MB.

Ther Adv Musculoskelet Dis. 2014 Oct;6(5):185-202. doi: 10.1177/1759720X14546350. Review.

10.

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Nishizawa S, Inagaki T, Iba A, Kikkawa K, Kodama Y, Matsumura N, Kohjimoto Y, Hara I.

Springerplus. 2014 Oct 8;3:586. doi: 10.1186/2193-1801-3-586. eCollection 2014.

11.

Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.

Graham-Steed TR, Soulos PR, Dearing N, Concato J, Tinetti ME, Gross CP.

J Geriatr Oncol. 2014 Oct 1;5(4):343-51. doi: 10.1016/j.jgo.2014.08.004. Epub 2014 Sep 18.

12.

Food Fortification and Supplement Use-Are There Health Implications?

Datta M, Vitolins MZ.

Crit Rev Food Sci Nutr. 2016 Oct 2;56(13):2149-59. doi: 10.1080/10408398.2013.818527. Review.

PMID:
25036360
14.

Eight-year survival and continuation of therapy in a patient suffering from prostate cancer with metastases and pathological fractures of vertebrae.

Dutkiewicz S, Poniatowska R.

Cent European J Urol. 2011;64(2):97-9. doi: 10.5173/ceju.2011.02.art12. Epub 2011 Jun 2.

15.

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.

Saylor PJ.

Asian J Androl. 2014 May-Jun;16(3):341-7. doi: 10.4103/1008-682X.122591. Review.

16.

Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, Lu SB, Peng J.

J Transl Med. 2013 Dec 11;11:303. doi: 10.1186/1479-5876-11-303. Review.

17.

Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.

McKay RR, Taplin ME, Choueiri TK.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix. doi: 10.1016/j.hoc.2013.08.009. Epub 2013 Sep 20. Review.

18.

Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence.

Sim IeW, Ebeling PR.

Ther Adv Musculoskelet Dis. 2013 Oct;5(5):259-67. doi: 10.1177/1759720X13500861.

19.

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.

Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35. Epub 2013 Oct 1.

20.

CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

Saad F, Hotte S, Catton C, Drachenberg D, Finelli A, Fleshner N, Gleave M, Kapoor A, Kassouf W, Loblaw A, North S, Usmani N, Chi KN.

Can Urol Assoc J. 2013 Jul-Aug;7(7-8):231-7. doi: 10.5489/cuaj.1542. No abstract available. Erratum in: Can Urol Assoc J. 2013 Sep;7(9-10):301.

Supplemental Content

Support Center